Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Safi, Sher Zaman ^a   Qvist, Rajes ^a   Kumar, Selva ^a   Batumalaie, Kalaivani ^a   Ismail, Ikram Shah Bin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; HEXOSAMINE; TRANSCRIPTION FACTOR; ADVANCED GLYCATION END PRODUCT; PROTEIN KINASE C;

APOPTOSIS; CELL SURVIVAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; MOLECULAR MECHANICS; RETINA CELL; REVIEW; RISK FACTOR; BLINDNESS; COMPLICATION; MACULAR EDEMA; METABOLISM; PATHOLOGY;

BLINDNESS; CELL SURVIVAL; DIABETIC RETINOPATHY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERGLYCEMIA; MACULAR EDEMA; PROTEIN KINASE C; RISK FACTORS;

EID: 84904819588     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/801269     Document Type: Review

References (149)

1. International Diabetes Federation,. Facts and figures, http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures
2. Pirart J., Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (Pt 1). Diabetes Care 1978 1 3 168 188 2-s2.0-0018225976 (Pubitemid 9171570)
3. Nguyen Q. D., Shah S. M., Khwaja A. A., Channa R., Hatef E., Do D. V., Boyer D., Heier J. S., Abraham P., Thach A. B., Lit E. S., Foster B. S., Kruger E., Dugel P., Chang T., Das A., Ciulla T. A., Pollack J. S., Lim J. I., Eliot D., Campochiaro P. A., Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2010 117 11 2146 2151 10.1016/j.ophtha.2010.08.016 2-s2.0-78049293726
4. Yau J. W., Rogers S. L., Kawasaki R., Lamoureux E. L., Kowalski J. W., Bek T., Chen S. J., Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012 35 3 556 564 10.2337/dc11-1909
5. Zheng Y., He M., Congdon N., The worldwide epidemic of diabetic retinopathy. Indian Journal of Ophthalmology 2012 60 5 428 431 10.4103/0301-4738.100542 2-s2.0-84866358054
6. Yau J. W., Rogers S. L., Kawasaki R., Global prevalence and major risk factors of diabetic retinopathy. Care. Diabetes Care 2012 35 556 564
7. Kempen J. H., O'Colmain B. J., Leske M. C., Haffner S. M., Klein R., Moss S. E., Taylor H. R., Hamman R. F., West S. K., Wang J. J., Congdon N. G., Friedman D. S., The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology 2004 122 4 552 563 10.1001/archopht. 122.4.552 2-s2.0-11144356305 (Pubitemid 38456292)
8. Harding S., Extracts from "concise clinical evidence": diabetic retinopathy. BMJ 2003 326 7397 1023 1025 10.1136/bmj.326.7397.1023 2-s2.0-0242696037
9. Diabetic Retinopathy Clinical trials: NHS choices. http://www.nhs.uk/ Conditions/Diabetic-retinopathy/Pages/clinical-trial.aspx
10. Pober J. S., Sessa W. C., Evolving functions of endothelial cells in inflammation. Nature Reviews Immunology 2007 7 10 803 815 10.1038/nri2171 2-s2.0-34748914299 (Pubitemid 47480307)
11. Sang D. N., D'Amore P. A., Is blockade of vascular endothelial growth factor beneficial for all types of diabetic retinopathy? Diabetologia 2008 51 9 1570 1573 10.1007/s00125-008-1078-9 2-s2.0-49249129275
12. Cilenšek I., Mankoč S., Petrovič M. G., Petrovič D., The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Molecular Biology Reports 2012 39 6 7061 7067 10.1007/s11033-012-1537-8 2-s2.0-84864280375
13. Balasubbu S., Sundaresan P., Rajendran A., Ramasamy K., Govindarajan G., Perumalsamy N., Hejtmancik J. F., Association analysis of nine candidate gene polymorphisms in Indian patients with type 2 diabetic retinopathy. BMC Medical Genetics 2010 11 1, article 158 10.1186/1471-2350-11-158 2-s2.0-78149267892
14. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1993 329 14 977 986
15. Mohamed Q., Gillies M. C., Wong T. Y., Management of diabetic retinopathy: a systematic review. Journal of the American Medical Association 2007 298 8 902 916 10.1001/jama.298.8.902 2-s2.0-34548087845 (Pubitemid 47311296)
16. Fong D. S., Girach A., Boney A., Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007 27 7 816 824 10.1097/IAE.0b013e318042d32c 2-s2.0-34748924210 (Pubitemid 47479374)
17. Centers for Disease Control and Prevention, Diabetes: minorities face greater burden. CDC National Diabetes Fact Sheet 2007 CDC. http://www.cdc.gov/ Features/dsDiabetes
18. Fong D. S., Aiello L., Gardner T. W., King G. L., Blankenship G., Cavallerano J. D., Ferris F. L., Klein R., Diabetic retinopathy. Diabetes Care 2003 26 1 226 229 10.2337/diacare.26.1.226 2-s2.0-0041743753 (Pubitemid 36934461)
19. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 6865 813 820 10.1038/414813a 2-s2.0-0035856980 (Pubitemid 34000785)
20. Dagher Z., Park Y. S., Asnaghi V., Hoehn T., Gerhardinger C., Lorenzi M., Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004 53 9 2404 2411 10.2337/diabetes.53.9.2404 2-s2.0-4344658774 (Pubitemid 39145596)
21. Gabbay K. H., The sorbitol pathway and the complications of diabetes. The New England Journal of Medicine 1973 288 16 831 836 10.1056/NEJM197304192881609 2-s2.0-0015929739
22. Oates P. J., Polyol pathway and diabetic peripheral neuropathy. International Review of Neurobiology 2002 50 325 392 10.1016/S0074-7742(02) 50082-9 2-s2.0-0036369809
23. Gabbay K. H., Purification and immunological identification of bovine retinal aldose reductase. Israel Journal of Medical Sciences 1972 8 8 1626 1629 2-s2.0-0015378692
24. Travis S. F., Morrison A. D., Clements R. S. Jr., Winegrad A. I., Oski F. A., The role of the polyol pathway in methaemoglobin reduction in human red cells. British Journal of Haematology 1974 27 4 597 605 10.1111/j.1365-2141. 1974.tb06625.x 2-s2.0-0016279479
25. Diabetes Mellitus: A Fundamental and Clinical Text 2000 Philadelphia, Pa, USA Lippincott Williams & Wilkins
26. Asnaghi V., Gerhardinger C., Hoehn T., Adeboje A., Lorenzi M., A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003 52 2 506 511 10.2337/diabetes.52. 2.506 2-s2.0-0037317423 (Pubitemid 36173210)
27. Obrosova I. G., Minchenko A. G., Vasupuram R., White L., Abatan O. I., Kumagai A. K., Frank R. N., Stevens M. J., Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003 52 3 864 871 10.2337/diabetes.52.3.864 2-s2.0-0344837811 (Pubitemid 36323597)
28. Hennekens C., A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Archives of Ophthalmology 1990 108 9 1234 1244 10.1001/archopht.1990.01070110050024 2-s2.0-0025073693 (Pubitemid 20295382)
29. Zong H., Ward M., Stitt A. W., AGEs, RAGE, and diabetic retinopathy. Current Diabetes Reports 2011 11 4 244 252 10.1007/s11892-011-0198-7 2-s2.0-80051599575
30. Singh R., Barden A., Mori T., Beilin L., Advanced glycation end-products: a review. Diabetologia 2001 44 2 129 146 10.1007/s001250051591 2-s2.0-0035135246 (Pubitemid 32156196)
31. Stitt A. W., Advanced glycation: an important pathological event in diabetic and age related ocular disease. British Journal of Ophthalmology 2001 85 6 746 753 10.1136/bjo.85.6.746 2-s2.0-0034985014 (Pubitemid 32554256)
32. Schmidt A. M., Hori O., Brett J., Wautier J., Stern D., Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arteriosclerosis and Thrombosis 1994 14 10 1521 1528 10.1161/01.ATV.14.10.1521 2-s2.0-0028068046
33. Goldin A., Beckman J. A., Schmidt A. M., Creager M. A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006 114 6 597 605 10.1161/CIRCULATIONAHA.106.621854 2-s2.0-33746920337 (Pubitemid 44199649)
34. Renard C., Chappey O., Wautier M., Nagashima M., Lundh E., Morser J., Zhao L., Schmidt A.-., Scherrmann J.-., Wautier J.-., Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Molecular Pharmacology 1997 52 1 54 62 2-s2.0-0030838112 (Pubitemid 27318618)
35. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., Vlassara H., Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. Journals of Gerontology A: Biological Sciences and Medical Sciences 2007 62 4 427 433 10.1093/gerona/62.4.427 2-s2.0-34250327529 (Pubitemid 47065712)
36. Mokini Z., Marcovecchio M. L., Chiarelli F., Molecular pathology of oxidative stress in diabetic angiopathy: role of mitochondrial and cellular pathways. Diabetes Research and Clinical Practice 2010 87 3 313 321 10.1016/j.diabres.2009.11.018 2-s2.0-77649189371
37. Kowluru R. A., Kowluru V., Xiong Y., Ho Y., Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radical Biology and Medicine 2006 41 8 1191 1196 10.1016/j.freeradbiomed.2006.01.012 2-s2.0-33749070956 (Pubitemid 44466317)
38. Kowluru R. A., Engerman R. L., Case G. L., Kern T. S., Retinal glutamate in diabetes and effect of antioxidants. Neurochemistry International 2001 38 5 385 390 10.1016/S0197-0186(00)00112-1 2-s2.0-0035104682 (Pubitemid 32166895)
39. Chan P., Kanwar M., Kowluru R. A., Resistance of retinal inflammatory mediators to suppress after reinstitution of good glycemic control: novel mechanism for metabolic memory. Journal of Diabetes and its Complications 2010 24 1 55 63 10.1016/j.jdiacomp.2008.10.002 2-s2.0-70749133081
40. Huang J., Guh J., Hung W., Yang M., Lai Y., Chen H., Chuang L., Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. Biochemical Journal 1999 342 1 231 238 10.1042/0264-6021:3420231 2-s2.0-0033567290 (Pubitemid 29410870)
41. Deora A. A., Win T., Vanhaesebroeck B., Lander H. M., A redox-triggered Ras-effector interaction: recruitment of phosphatidylinositol 3′-kinase to Ras by redox stress. The Journal of Biological Chemistry 1998 273 45 29923 29928 10.1074/jbc.273.45.29923 2-s2.0-0032491398 (Pubitemid 28510008)
42. 2+ signaling of cultured human mesangial cells. Journal of the American Society of Nephrology 1999 10 7 1478 1486 2-s2.0-0033034122 (Pubitemid 29297522)
43. ras -dependent mitogen-activated protein kinase pathway regulated by oxidant stress. The Journal of Biological Chemistry 1997 272 28 17810 17814 10.1074/jbc.272.28.17810 2-s2.0-0030859290 (Pubitemid 27311222)
44. Sugiyama S., Miyata T., Ueda Y., Tanaka H., Maeda K., Kawashima S., Van Ypersele De Strihou C., Kurokawa K., Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. Journal of the American Society of Nephrology 1998 9 9 1681 1688 2-s2.0-0031752572
45. Wautier M. P., Massin P., Guillausseau P. J., Huijberts M., Levy B., Boulanger E., Laloi-Michelin M., Wautiere J. L., N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes and Metabolism 2003 29 1 44 52 10.1016/S1262-3636(07)70006-X 2-s2.0-0037301293 (Pubitemid 36362615)
46. Yamagishi S., Fujimori H., Yonekura H., Yamamoto Y., Yamamoto H., Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia 1998 41 12 1435 1441 10.1007/s001250051089 2-s2.0-0031773362 (Pubitemid 28551614)
47. Okamoto T., Yamagishi S., Inagaki Y., Amano S., Koga K., Abe R., Takeuchi M., Ohno S., Yoshimura A., Makita Z., Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. The FASEB Journal 2002 16 14 1928 1930 2-s2.0-0036884617
48. Okamoto T., Yamagishi S., Inagaki Y., Inhibition of high glucose-induced VEGF and ICAM-1 expression in human retinal pigment epithelium cells by targeting ILK with small interference RNA. Molecular Biology Reports 2001 39 1 613 620 10.1007/s11033-011-0778-2
49. Wang W., Matsukura M., Fujii I., Ito K., Zhao J. E., Shinohara M., Wang Y. Q., Zhang X. M., Inhibition of high glucose-induced VEGF and ICAM-1 expression in human retinal pigment epithelium cells by targeting ILK with small interference RNA. Molecular Biology Reports 2012 39 1 613 620 10.1007/s11033-011-0778-2 2-s2.0-84855198209
50. Yang C., Vlassara H., Peten E. P., He C., Striker G. E., Striker L. J., Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proceedings of the National Academy of Sciences of the United States of America 1994 91 20 9436 9440 10.1073/pnas.91.20.9436 2-s2.0-0027937056 (Pubitemid 24297929)
51. Giacco F., Brownlee M., Oxidative stress and diabetic complications. Circulation Research 2010 107 9 1058 1070 10.1161/CIRCRESAHA.110.223545 2-s2.0-78349297565
52. Nerlich A. G., Sauer U., Kolm-Litty V., Wagner E., Koch M., Schleicher E. D., Expression of glutamine: fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 1998 47 2 170 178 10.2337/diab.47.2.170 2-s2.0-0031938518 (Pubitemid 28079970)
53. Schleicher E. D., Weigert C., Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney International, Supplement 2000 58 77 S13 S18 10.1046/j.1523-1755.2000.07703.x 2-s2.0-0033852661
54. Comer F. I., Hart G. W., O -glycosylation of nuclear and cytosolic proteins. Dynamic interplay between O -GlcNAc and O -phosphate. The Journal of Biological Chemistry 2000 275 38 29179 29182 10.1074/jbc.R000010200 2-s2.0-0034703095 (Pubitemid 32043784)
55. Wells L., Vosseller K., Hart G. W., Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 2001 291 5512 2376 2378 10.1126/science.1058714 2-s2.0-0035937586 (Pubitemid 32231793)
56. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E. D., High glucose-induced transforming growth factor β 1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation 1998 101 1 160 169 10.1172/JCI119875 2-s2.0-0031975643 (Pubitemid 28058915)
57. Li Y., Roux C., Lazereg S., Identification of a novel serine phosphorylation site in human glutamine: fructose-6-phosphate amidotransferase isoform 1. Biochemistry 2007 46 45 13163 13169 10.1021/bi700694c (Pubitemid 350086234)
58. Nakamura M., Barber A. J., Antonetti D. A., LaNoue K. F., Robinson K. A., Buse M. G., Gardner T. W., Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. The Journal of Biological Chemistry 2001 276 47 43748 43755 10.1074/jbc.M108594200 2-s2.0-0035941260
59. Yki-Järvinen H., Daniels M. C., Virkamäki A., Mäkimattila S., DeFronzo R. A., McClain D., Increased glutamine: fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 1996 45 3 302 307 10.2337/diab.45.3.302 2-s2.0-0030042488 (Pubitemid 26069043)
60. Du X., Edelstein D., Rossetti L., Fantus I. G., Goldberg H., Ziyadeh F., Wu J., Brownlee M., Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proceedings of the National Academy of Sciences of the United States of America 2000 97 22 12222 12226 10.1073/pnas.97.22.12222 2-s2.0-0034710891
61. Chen Y. Q., Su M., Walia R. R., Hao Q., Covington J. W., Vaughan D. E., Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. Journal of Biological Chemistry 1998 273 14 8225 8231 10.1074/jbc.273.14.8225 2-s2.0-0032478827 (Pubitemid 28168879)
62. Geraldes P., King G. L., Activation of protein kinase C isoforms and its impact on diabetic complications. Circulation Research 2010 106 8 1319 1331 10.1161/CIRCRESAHA.110.217117 2-s2.0-77952468064
63. Rosse C., Linch M., Kermorgant S., Cameron A. J. M., Boeckeler K., Parker P. J., PKC and the control of localized signal dynamics. Nature Reviews Molecular Cell Biology 2010 11 2 103 112 10.1038/nrm2847 2-s2.0-75149161903
64. Xia P., Inoguchi T., Kern T. S., Engerman R. L., Oates P. J., King G. L., Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994 43 9 1122 1129 10.2337/diab.43.9.1122 2-s2.0-0027981889 (Pubitemid 24265474)
65. Koya D., King G. L., Protein kinase C activation and the development of diabetic complications. Diabetes 1998 47 6 859 866 10.2337/diabetes.47.6.859 2-s2.0-0031860340 (Pubitemid 28255657)
66. Lorenzi M., The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Experimental Diabesity Research 2007 2007 10 61038 10.1155/2007/61038 2-s2.0-34547935418 (Pubitemid 47263650)
67. Obrosova I. G., Kador P. F., Aldose reductase/polyol inhibitors for diabetic retinopathy. Current Pharmaceutical Biotechnology 2011 12 3 373 385 10.2174/138920111794480642 2-s2.0-79551676547
68. Hao H. H., Shao Z. M., Tang D. Q., Lu Q., Chen X., Yin X., Wu J., Chen H., Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. Life Sciences 2012 91 19-20 959 967 10.1016/j.lfs.2012.09. 003 2-s2.0-84867849002
69. Srivastava A. K., High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes. International Journal of Molecular Medicine 2002 9 1 85 89 2-s2.0-0036134050
70. Witmer A. N., Vrensen G. F., van Noorden C. J., Schlingemann R. O., Vascular endothelial growth factors and angiogenesis in eye disease. Progress in Retinal and Eye Research 2003 22 1 1 29 10.1016/S1350-9462(02)00043-5 2-s2.0-0037277741 (Pubitemid 36207453)
71. Kitada M., Koya D., Sugimoto T., Isono M., Araki S., Kashiwagi A., Haneda M., Translocation of glomerular p47phox and p67phox by protein kinase C- β activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003 52 10 2603 2614 10.2337/diabetes.52.10.2603 2-s2.0-0141755311 (Pubitemid 37210551)
72. The Diabetes Control and Complications Trial Research Group, Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995 102 4 647 661 10.1016/S0161-6420(95)30973-6
73. van Leiden H. A., Dekker J. M., Moll A. C., Nijpels G., Heine R. J., Bouter L. M., Stehouwer C. D. A., Polak B. C. P., Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn Study. Diabetes Care 2002 25 8 1320 1325 10.2337/diacare.25.8.1320 2-s2.0-0036673902 (Pubitemid 41071139)
74. Sharma S., Brown G. C., Brown M. M., Hollands H., Shah G. K., The cost-effectiveness of grid laser photocoagulation for the treatment of diabetic macular edema: results of a patient-based cost-utility analysis. Current Opinion in Ophthalmology 2000 11 3 175 179 10.1097/00055735-200006000-00004 2-s2.0-0034045134 (Pubitemid 30341562)
75. Diabetic Retinopathy Study Research Group, Photocoagulation treatment of proliferative diabetic retinopathy: the second report of DRS findings. Ophthalmology 1978 85 1 82 106 10.1016/S0161-6420(78)35693-1
76. Early Treatment Diabetic Retinopathy Study Research Group, Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology 1991 98 5 766 785
77. Early Treatment Diabetic Retinopathy Study Research Group, Design and baseline patient characteristics. ETDRS report no. 7. Ophthalmology 1991 98 741 756 10.1016/S0161-6420(13)38009-9
78. Brownlee M., Vlassara H., Cerami A., Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Annals of Internal Medicine 1984 101 4 527 537 10.7326/0003-4819-101-4-527 2-s2.0-0021231172 (Pubitemid 14018054)
79. Waldhaäusl W. K., Diabetes 1979. Proceedings of the 10th Congress of the International Diabetes Federation September 1980 Vienna, Austria Excerpta Medica
80. Diabetic Retinopathy Vitrectomy Study Research Group, Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. DRVS report no. 1. Ophthalmology 1985 92 492 502
81. The Diabetic Retinopathy Study Research Group, Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981 88 7 583 600
82. Park K., Lee K., Zhang B., Zhou T., He X., Gao G., Murray A. R., Ma J., Identification of a novel inhibitor of the canonical Wnt pathway. Molecular and Cellular Biology 2011 31 14 3038 3051 10.1128/MCB.01211-10 2-s2.0-79960341497
83. Sheikpranbabu S., Haribalaganesh R., Gurunathan S., Pigment epithelium-derived factor inhibits advanced glycation end-products-induced cytotoxicity in retinal pericytes. Diabetes & Metabolism 2011 37 6 505 511 10.1016/j.diabet.2011.03.006 2-s2.0-83255187388
84. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., Imaizumi T., Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvascular Research 2006 72 1-2 86 90 10.1016/j.mvr.2006.04.002 2-s2.0-33746353693 (Pubitemid 44118388)
85. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G., Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991 40 10 1328 1334 10.2337/diab.40.10.1328 2-s2.0-0026063185
86. Marx N., Walcher D., Ivanova N., Rautzenberg K., Jung A., Friedl R., Hombach V., De Caterina R., Basta G., Wautier M., Wautiers J., Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004 53 10 2662 2668 10.2337/diabetes.53.10. 2662 2-s2.0-4644342944 (Pubitemid 39299276)
87. Yamagishi S., Takeuchi M., Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation. Drugs under Experimental and Clinical Research 2004 30 4 169 175 2-s2.0-8444249207 (Pubitemid 39487685)
88. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., Imaizumi T., Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvascular Research 2005 70 3 137 141 10.1016/j.mvr.2005.10.002 2-s2.0-27744574284 (Pubitemid 41586467)
89. Agardh E., Hultberg B., Agardh C.-D., Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. Current Eye Research 2000 21 1 543 549 10.1076/0271-3683(200007)2111-ZFT543 2-s2.0-0033733494
90. Picard S., Parthasarathy S., Fruebis J., Witztum J. L., Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proceedings of the National Academy of Sciences of the United States of America 1992 89 15 6876 6880 10.1073/pnas.89.15.6876 2-s2.0-0026625832
91. Grattagliano I., Vendemiale G., Boscia F., Micelli-Ferrari T., Cardia L., Altomare E., Oxidative retinal products and ocular damages in diabetic patients. Free Radical Biology and Medicine 1998 25 3 369 372 10.1016/S0891-5849(98)00059-8 2-s2.0-0032145856 (Pubitemid 28326213)
92. Hartnett M. E., Stratton R. D., Browne R. W., Rosner B. A., Lanham R. J., Armstrong D., Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000 23 2 234 240 10.2337/diacare.23.2.234 2-s2.0-0033979291 (Pubitemid 30071030)
93. Robison W. G. Jr., Jacot J. L., Katz M. L., Glover J. P., Retinal vascular changes induced by the oxidative stress of α-tocopherol deficiency contrasted with diabetic microangiopathy. Journal of Ocular Pharmacology and Therapeutics 2000 16 2 109 120 10.1089/jop.2000.16.109 2-s2.0-0342313587 (Pubitemid 30235970)
94. Liao D., Monia B., Dean N., Berk B. C., Protein kinase C- ζ mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. Journal of Biological Chemistry 1997 272 10 6146 6150 10.1074/jbc.272.10.6146 2-s2.0-0030892639 (Pubitemid 27118081)
95. Ishii H., Jirousek M. R., Koya D., Takagi C., Xia P., Clermont A., Bursell S., Kern T. S., Ballas L. M., Heath W. F., Stramm L. E., Feener E. P., King G. L., Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996 272 5262 728 731 10.1126/science.272.5262.728 2-s2.0-13344293711 (Pubitemid 26000279)
96. Davis M. D., Sheetz M. J., Aiello L. P., Milton R. C., Danis R. P., Zhi X., Girach A., Jimenez M. C., Vignati L., Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Investigative Ophthalmology and Visual Science 2009 50 1 1 4 10.1167/iovs.08-2473 2-s2.0-58249089758
97. Gálvez M. I. L., Rubosixtaurin and other pkc inhibitors in diabetic retinopathy and macular Edema. Review. Current Diabetes Reviews 2009 5 1 14 17 10.2174/157339909787314167 2-s2.0-65549122820
98. Geraldes P., Hiraoka-Yamamoto J., Matsumoto M., Clermont A., Leitges M., Marette A., Aiello L. P., Kern T. S., King G. L., Activation of PKC-and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nature Medicine 2009 15 11 1298 1306 10.1038/nm.2052 2-s2.0-70449108112
99. Koya D., Jirousek M. R., Lin Y., Ishii H., Kuboki K., King G. L., Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor- β extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. Journal of Clinical Investigation 1997 100 1 115 126 10.1172/JCI119503 2-s2.0-0030760729 (Pubitemid 27311249)
100. Bursell S., Clermont A. C., Aiello L. P., Aiello L. M., Schlossman D. K., Feener E. P., Laffel L., King G. L., High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care 1999 22 8 1245 1251 10.2337/diacare.22.8.1245 2-s2.0-0032813888 (Pubitemid 29350231)
101. Xia P., Aiello L. P., Ishii H., Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. The Journal of Clinical Investigation 1996 98 9 2018 2026 10.1172/JCI119006 (Pubitemid 26376289)
102. Aiello L. P., Bursell S. E., Clermont A., Duh E., Ishii H., Takagi C., Mori F., Ciulla T. A., Ways K., Jirousek M., Smith L. E. H., King G. L., Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β -isoform-selective inhibitor. Diabetes 1997 46 9 1473 1480 10.2337/diab.46.9. 1473 2-s2.0-15644366961 (Pubitemid 27369086)
103. Harhaj N. S., Felinski E. A., Wolpert E. B., Sundstrom J. M., Gardner T. W., Antonetti D. A., VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Investigative Ophthalmology and Visual Science 2006 47 11 5106 5115 10.1167/iovs.06-0322 2-s2.0-33947313405 (Pubitemid 46586418)
104. Teng Y., Cui H., Yang M., Protective effect of puerarin on diabetic retinopathy in rats. Molecular Biology Reports 2009 36 5 1129 1133 10.1007/s11033-008-9288-2
105. Sheetz M. J., King G. L., Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Journal of the American Medical Association 2002 288 20 2579 2588 10.1001/jama.288.20.2579 2-s2.0-0037184495 (Pubitemid 35386893)
106. Kelly D. J., Zhang Y., Hepper C., Gow R. M., Jaworski K., Kemp B. E., Wilkinson-Berka J. L., Gilbert R. E., Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003 52 2 512 518 10.2337/diabetes.52.2.512 2-s2.0-0037315791 (Pubitemid 36173211)
107. Tuttle K. R., Bakris G. L., Toto R. D., McGill J. B., Hu K., Anderson P. W., The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005 28 11 2686 2690 10.2337/diacare.28.11.2686 2-s2.0-28644442122 (Pubitemid 43951160)
108. Oates P. J., Mylari B. L., Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opinion on Investigational Drugs 1999 8 12 2095 2119 10.1517/13543784.8.12.2095 2-s2.0-0032693720
109. Hayman S., Kinoshita J. H., solation and properties of lens aldose reductase. The Journal of Biological Chemistry 1965 240 877 882 2-s2.0-0000930578
110. Obrosova I. G., Pacher P., Szabó C., Zsengeller Z., Hirooka H., Stevens M. J., Yorek M. A., Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes 2005 54 1 234 242 10.2337/diabetes.54.1.234 2-s2.0-12144279066 (Pubitemid 40105118)
111. Drel V. R., Pacher P., Ali T. K., Shin J., Julius U., El-Remessy A. B., Obrosova I. G., Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. International Journal of Molecular Medicine 2008 21 6 667 676 2-s2.0-47649126432
112. Obrosova I. G., Maksimchyk Y., Pacher P., Agardh E., Smith M., El-Remessy A. B., Agardh C., Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. International Journal of Molecular Medicine 2010 26 1 135 142 10.3892/ijmm-00000445 2-s2.0-77954735649
113. Hattori T., Matsubara A., Taniguchi K., Ogura Y., Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo. Current Eye Research 2010 35 2 146 154 10.3109/02713680903447918 2-s2.0-76749085691
114. Drel V. R., Xu W., Zhang J., Kador P. F., Ali T. K., Shin J., Julius U., Slusher B., El-Remessy A. B., Obrosova I. G., Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats. Investigative Ophthalmology and Visual Science 2009 50 4 1778 1790 10.1167/iovs.08-2191 2-s2.0-64049094318
115. Sima A. A. F., Bril V., Nathaniel V., McEwen T. A. J., Brown M. B., Lattimer S. A., Greene D. A., Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. The New England Journal of Medicine 1988 319 9 548 555 10.1056/NEJM198809013190905 2-s2.0-0023748415
116. Greene D. A., Arrezo J., Brown M., Dose-related effects of the aldose reductase inhibitor Zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fiber density in human diabetic neuropathy. Diabetes 1996 45 supplement 2, article 5A
117. Kim J., Kim C.-S., Sohn E., Lee Y. M., Kim J. S., KIOM-79 inhibits aldose reductase activity and cataractogenesis in Zucker diabetic fatty rats. Journal of Pharmacy and Pharmacology 2011 63 10 1301 1308 10.1111/j.2042-7158.2011. 01341.x 2-s2.0-80052576355
118. Engerman R. L., Kern T. S., Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 1993 42 6 820 825 10.2337/diab.42.6.820 2-s2.0-0027271798 (Pubitemid 23151573)
119. Kador P. F., Akagi Y., Takahashi Y., Ikebe H., Wyman M., Kinoshita J. H., Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Archives of Ophthalmology 1990 108 9 1301 1309 10.1001/archopht.1990.01070110117035 2-s2.0-0025140713 (Pubitemid 20295393)
120. Greene D. A., Arezzo J. C., Brown M. B., Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999 53 3 580 591 10.1212/WNL.53.3.580 2-s2.0-0033546655 (Pubitemid 29382055)
121. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813 820 10.1038/414813a (Pubitemid 34000785)
122. Du J., Wang L., Liu X., Zhou H., Fan Q., Luo J., Yao L., Wang J., Feng J., Ma J., Janus kinase 2/signal transducers and activators of transcription signal inhibition regulates protective effects of probucol on mesangial cells treated with high glucose. Biological and Pharmaceutical Bulletin 2010 33 5 768 772 10.1248/bpb.33.768 2-s2.0-77952411997
123. Rajapakse A. G., Ming X. F., Carvas J. M., Yang Z., The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects. American Journal of Physiology-Heart and Circulatory Physiology 2009 296 3 H815 H822 10.1152/ajpheart.00756.2008 2-s2.0-64049093074
124. Hull R. L., Zraika S., Udayasankar J., Kisilevsky R., Szarek W. A., Wight T. N., Kahn S. E., Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. The American Journal of Physiology-Cell Physiology 2007 293 5 C1586 C1593 10.1152/ajpcell.00208.2007 2-s2.0-36048998707 (Pubitemid 350085645)
125. Zheng J. M., Zhu J. M., Li L. S., Liu Z.-H., Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway. British Journal of Pharmacology 2008 153 7 1456 1464 10.1038/bjp.2008.26 2-s2.0-41649096963 (Pubitemid 351481522)
126. Hammes H., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., Lin J., Bierhaus A., Nawroth P., Hannak D., Neumaier M., Bergfeld R., Giardino I., Brownlee M., Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine 2003 9 3 294 299 10.1038/nm834 2-s2.0-0344837347 (Pubitemid 36362784)
127. Laight D. W., Carrier M. J., Anggard E. E., Antioxidants, diabetes and endothelial dysfunction. Cardiovascular Research 2000 47 3 457 464 10.1016/S0008-6363(00)00054-7 2-s2.0-0034683051 (Pubitemid 30646068)
128. Packer L., Witt E. H., Tritschler H. J., Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine 1995 19 2 227 250 10.1016/0891-5849(95)00017-R 2-s2.0-0029070687
129. Kowluru R. A., Odenbach S., Effect of long-term administration of α -lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 2004 53 12 3233 3238 10.2337/diabetes.53.12.3233 2-s2.0-9444224415 (Pubitemid 39564500)
130. Scott J. A., King G. L., Oxidative stress and antioxidant treatment in diabetes. Annals of the New York Academy of Sciences 2004 1031 204 213 10.1196/annals.1331.020 2-s2.0-14944340746 (Pubitemid 40361755)
131. Mustata G. T., Rosca M., Biemel K. M., Reihl O., Smith M. A., Viswanathan A., Strauch C., Du Y., Tang J., Kern T. S., Lederer M. O., Brownlee M., Weiss M. F., Monnier V. M., Paradoxical effects of green tea (Camellia sinensis) and antioxidant vitamins in diabetic rats: improved retinopathy and renal mitochondrial defects but deterioration of collagen matrix glycoxidation and cross-linking. Diabetes 2005 54 2 517 526
132. Kumari S., Panda S., Mangaraj M., Mandal M. K., Mahapatra P. C., Plasma MDA and antioxidant vitamins in diabetic retinopathy. Indian Journal of Clinical Biochemistry 2008 23 2 158 162 10.1007/s12291-008-0035-1 2-s2.0-51349114611
133. Kowluru R. A., Zhong Q., Santos J. M., Thandampallayam M., Putt D., Gierhart D. L., Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutrition & Metabolism 2014 11 1, article 8 10.1186/1743-7075-11-8
134. Shohami E., Gallily R., Mechoulam R., Bass R., Ben-Hur T., Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF- α inhibitor and an effective neuroprotectant. Journal of Neuroimmunology 1997 72 2 169 177 10.1016/S0165-5728(96)00181-6 2-s2.0-0031047431 (Pubitemid 27062773)
135. Hampson A. J., Grimaldi M., Axelrod J., Wink D., Cannabidiol and (-) Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America 1998 95 14 8268 8273 10.1073/pnas.95.14.8268 2-s2.0-0032493197 (Pubitemid 28326102)
136. Liou G. I., Auchampach J. A., Hillard C. J., Zhu G., Yousufzai B., Mian S., Khan S., Khalifa Y., Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Investigative Ophthalmology and Visual Science 2008 49 12 5526 5531 10.1167/iovs.08-2196 2-s2.0-58149269741
137. Braida D., Pegorini S., Arcidiacono M. V., Consalez G. G., Croci L., Sala M., Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neuroscience Letters 2003 346 1-2 61 64 10.1016/S0304-3940(03)00569-X 2-s2.0-0037707636 (Pubitemid 36792194)
138. El-Remessy A. B., Ali Behzadian M., Abou-Mohamed G., Franklin T., Caldwell R. W., Caldwell R. B., Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. The American Journal of Pathology 2003 162 6 1995 2004 10.1016/S0002-9440(10)64332-5 2-s2.0-0038243821 (Pubitemid 36613056)
139. Wagner J., Danser A. H. J., Derkx F. H. M., De Jong P. T. V. M., Paul M., Mullins J. J., Schalekamp M. A. D. H., Ganten D., Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system. British Journal of Ophthalmology 1996 80 2 159 163 10.1136/bjo.80.2.159 2-s2.0-0030040965 (Pubitemid 26058551)
140. Wright A. D., Dodson P. M., Diabetic retinopathy and blockade of the renin-angiotensin system: New data from the DIRECT study programme. Eye 2010 24 1 1 6 10.1038/eye.2009.189 2-s2.0-75449093415
141. Klein R., Zinman B., Gardiner R., Suissa S., Donnelly S. M., Sinaiko A. R., Kramer M. S., Goodyer P., Moss S. E., Strand T., Mauer M., The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients: the renin-angiotensin system study. Diabetes 2005 54 2 527 533 10.2337/diabetes.54.2.527 2-s2.0-19944432411
142. Mancini G. B., Henry G. C., Macaya C., Angiotensin-converting enzyme inhibitor with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996 94 258 265 2-s2.0-0029792552 (Pubitemid 26266107)
143. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 2000 342 3 145 153 10.1056/NEJM200001203420301 2-s2.0-0034688194 (Pubitemid 30051645)
144. Chaturvedi M., Sjolie A. K., Stephenson J. M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J. H., Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The Lancet 1998 351 9095 28 31 10.1016/S0140-6736(97)06209-0 2-s2.0-0032477583 (Pubitemid 28020163)
145. Satofuka S., Ichihara A., Nagai N., Noda K., Ozawa Y., Fukamizu A., Tsubota K., Itoh H., Oike Y., Ishida S., (Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009 58 7 1625 1633 10.2337/db08-0254 2-s2.0-67650236573
146. Koshy J., Koshy J. M., Thomas S., Kaur G., Mathew T., Should we start all patients with diabetic retinopathy on fenofibrates? Middle East African Journal of Ophthalmology 2013 20 4 309 314 10.4103/0974-9233.120012
147. Keech A., Mitchell P., Summanen P., O'Day J., Davis T., Moffitt M., Taskinen M., Simes R., Tse D., Williamson E., Merrifield A., Laatikainen L., d'Emden M., Crimet D., O'Connell R., Colman P., Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet 2007 370 9600 1687 1697 10.1016/S0140-6736(07) 61607-9 2-s2.0-36049001784 (Pubitemid 350100775)
148. Simó R., Hernández C., Fenofibrate for diabetic retinopathy. The Lancet 2007 370 9600 1667 1668 10.1016/S0140-6736(07)61608-0 2-s2.0-36048985669 (Pubitemid 350100776)
149. ACCORD Study Group and ACCORD Eye Study Group, Effects of medical therapies on retinopathy progression in type 2 diabetes. New England Journal of Medicine 2010 363 233 244 10.1056/NEJMoa1001288